comparemela.com

Latest Breaking News On - Zentalis pharmaceutical - Page 1 : comparemela.com

Zentalis Pharmaceuticals, Inc. (NASDAQ:ZNTL) Forecasted to Earn FY2027 Earnings of ($2.59) Per Share

Zentalis Pharmaceuticals, Inc. (NASDAQ:ZNTL – Free Report) – Analysts at Leerink Partnrs issued their FY2027 earnings per share estimates for shares of Zentalis Pharmaceuticals in a report released on Tuesday, February 27th. Leerink Partnrs analyst A. Berens anticipates that the company will earn ($2.59) per share for the year. Leerink Partnrs currently has a “Market […]

Stifel-nicolaus
Leerink-partnrs
Melissab-epperly
Zentalis-pharmaceuticals
Eventide-asset-management
Zentalis-pharmaceuticals-company-profile
Morgan-stanley
Zentalis-pharmaceuticals-stock-down
Institutional-investors-weigh-in-on-zentalis-pharmaceuticals
News-ratings-for-zentalis-pharmaceuticals-daily
Zentalis-pharmaceuticals-inc
Nasdaq

Leerink Partnrs Weighs in on Zentalis Pharmaceuticals, Inc.'s Q3 2023 Earnings (NASDAQ:ZNTL)

Leerink Partnrs Weighs in on Zentalis Pharmaceuticals, Inc.'s Q3 2023 Earnings (NASDAQ:ZNTL)
theenterpriseleader.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from theenterpriseleader.com Daily Mail and Mail on Sunday newspapers.

Stifel-nicolaus
Leerink-partnrs
Matrix-capital-management-company
News-ratings-for-zentalis-pharmaceuticals-daily
Nasdaq
Wells-fargo-company
Insider-transactions-at-zentalis-pharmaceuticals
Zentalis-pharmaceuticals-inc
Pricet-rowe-associates-inc
Jefferies-financial-group
Zentalis-pharmaceuticals

GSK (NYSE:GSK) & Zentalis Pharmaceuticals (NASDAQ:ZNTL) Head-To-Head Review

GSK (NYSE:GSK – Get Free Report) and Zentalis Pharmaceuticals (NASDAQ:ZNTL – Get Free Report) are both medical companies, but which is the superior business? We will contrast the two companies based on the strength of their earnings, risk, analyst recommendations, dividends, institutional ownership, valuation and profitability. Volatility and Risk GSK has a beta of 0.67, […]

Brentford
Hounslow
United-kingdom
United-states
New-york
Glaxosmithkline
Zentalis-pharmaceuticals-inc
Zentalis-pharmaceuticals
Pfizer-inc
Recurium-ip-holdings
Get-free-report

Q2 2023 EPS Estimates for Zentalis Pharmaceuticals, Inc. Cut by Analyst (NASDAQ:ZNTL)

Zentalis Pharmaceuticals, Inc. (NASDAQ:ZNTL – Get Rating) – Investment analysts at HC Wainwright decreased their Q2 2023 earnings per share estimates for shares of Zentalis Pharmaceuticals in a research note issued to investors on Thursday, May 11th. HC Wainwright analyst A. Fein now expects that the company will earn ($1.15) per share for the quarter, […]

Stifel-nicolaus
Pricet-rowe-associates-inc
Institutional-trading-of-zentalis-pharmaceuticals
Vanguard-group-inc
Zentalis-pharmaceuticals-stock-down
Zentalis-pharmaceuticals-inc
Nasdaq
Blackrock-inc
News-ratings-for-zentalis-pharmaceuticals-daily
Zentalis-pharmaceuticals
Get-rating
Zentalis-pharmaceutical

© 2024 Vimarsana

vimarsana © 2020. All Rights Reserved.